Literature DB >> 16896666

Imaging the neurobiological substrate of atypical depression by SPECT.

Marco Pagani1, Dario Salmaso, Davide Nardo, Cathrine Jonsson, Hans Jacobsson, Stig A Larsson, Ann Gardner.   

Abstract

PURPOSE: Neurobiological abnormalities underlying atypical depression have previously been suggested. The purpose of this study was to explore differences at functional brain imaging between depressed patients with and without atypical features and healthy controls.
METHODS: Twenty-three out-patients with chronic depressive disorder recruited from a service for patients with audiological symptoms were investigated. Eleven fulfilled the DSM-IV criteria for atypical depression (mood reactivity and at least two of the following: weight gain, hypersomnia, leaden paralysis and interpersonal rejection sensitivity). Twenty-three healthy subjects served as controls. Voxel-based analysis was applied to explore differences in (99m)Tc-HMPAO uptake between groups.
RESULTS: Patients in the atypical group had a higher prevalence of bilateral hearing impairment and higher depression and somatic distress ratings at the time of SPECT. Significantly higher tracer uptake was found bilaterally in the atypical group as compared with the non-atypicals in the sensorimotor (Brodmann areas, BA1-3) and premotor cortex in the superior frontal gyri (BA6), in the middle frontal cortex (BA8), in the parietal associative cortex (BA5, BA7) and in the inferior parietal lobule (BA40). Significantly lower tracer distribution was found in the right hemisphere in the non-atypicals compared with the controls in BA6, BA8, BA44, BA45 and BA46 in the frontal cortex, in the orbito-frontal cortex (BA11, BA47), in the postcentral parietal cortex (BA2) and in the multimodal association parietal cortex (BA40).
CONCLUSION: The differences found between atypical and non-atypical depressed patients suggest different neurobiological substrates in these patient groups. The putative links with the clinical features of atypical depression are discussed. These findings encourage the use of functional neuroimaging in psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896666     DOI: 10.1007/s00259-006-0177-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  37 in total

1.  Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study.

Authors:  E A Stamatakis; M F Glabus; D J Wyper; A Barnes; J T Wilson
Journal:  Neuroimage       Date:  1999-10       Impact factor: 6.556

2.  Cerebral blood flow in depressed patients: a methodological comparison of statistical parametric mapping and region of interest analyses.

Authors:  Omer Bonne; Yoram Louzoun; Itzhak Aharon; Yodphat Krausz; Haim Karger; Bernard Lerer; Moshe Bocher; Nanette Freedman; Roland Chisin
Journal:  Psychiatry Res       Date:  2003-01-20       Impact factor: 3.222

Review 3.  Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders.

Authors:  W C Drevets
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

4.  Skeletal muscle morphology of depressed patients after medication.

Authors:  J Ross-Stanton; H Y Meltzer
Journal:  Muscle Nerve       Date:  1979 May-Jun       Impact factor: 3.217

5.  Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression.

Authors:  G Rajkowska; J J Miguel-Hidalgo; J Wei; G Dilley; S D Pittman; H Y Meltzer; J C Overholser; B L Roth; C A Stockmeier
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

6.  All roads lead to depression: clinically homogeneous, etiologically heterogeneous.

Authors:  G Winokur
Journal:  J Affect Disord       Date:  1997-08       Impact factor: 4.839

Review 7.  Atypical depression: a reappraisal.

Authors:  Gordon Parker; Kay Roy; Philip Mitchell; Kay Wilhelm; Gin Malhi; Dusan Hadzi-Pavlovic
Journal:  Am J Psychiatry       Date:  2002-09       Impact factor: 18.112

8.  Hearing loss and asymmetry in major depression.

Authors:  Y Yovell; H A Sackeim; D G Epstein; J Prudic; D P Devanand; M C McElhiney; J M Settembrino; G E Bruder
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1995       Impact factor: 2.198

9.  Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18.

Authors:  L R Baxter; M E Phelps; J C Mazziotta; J M Schwartz; R H Gerner; C E Selin; R M Sumida
Journal:  Arch Gen Psychiatry       Date:  1985-05

10.  The anatomy of melancholia--focal abnormalities of cerebral blood flow in major depression.

Authors:  C J Bench; K J Friston; R G Brown; L C Scott; R S Frackowiak; R J Dolan
Journal:  Psychol Med       Date:  1992-08       Impact factor: 7.723

View more
  4 in total

1.  Effects of aging on circadian patterns of gene expression in the human prefrontal cortex.

Authors:  Cho-Yi Chen; Ryan W Logan; Tianzhou Ma; David A Lewis; George C Tseng; Etienne Sibille; Colleen A McClung
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-22       Impact factor: 11.205

2.  Altered slow wave activity in major depressive disorder with hypersomnia: a high density EEG pilot study.

Authors:  David T Plante; Eric C Landsness; Michael J Peterson; Michael R Goldstein; Tim Wanger; Jeff J Guokas; Giulio Tononi; Ruth M Benca
Journal:  Psychiatry Res       Date:  2012-04-16       Impact factor: 3.222

3.  Differences at brain SPECT between depressed females with and without adult ADHD and healthy controls: etiological considerations.

Authors:  Ann Gardner; Dario Salmaso; Andrea Varrone; Alejandro Sanchez-Crespo; Susanne Bejerot; Hans Jacobsson; Stig A Larsson; Marco Pagani
Journal:  Behav Brain Funct       Date:  2009-09-01       Impact factor: 3.759

Review 4.  The Legacy of the TTASAAN Report-Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I.

Authors:  Dan G Pavel; Theodore A Henderson; Simon DeBruin
Journal:  Front Neurol       Date:  2022-03-28       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.